keyword
MENU ▼
Read by QxMD icon Read
search

Anti-VEGF

keyword
https://www.readbyqxmd.com/read/29148027/sequential-tissue-plasminogen-activator-pneumatic-displacement-and-anti-vegf-treatment-for-submacular-hemorrhage
#1
Handan Bardak, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, Semrin Timlioglu
PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day...
November 4, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29146648/economic-evaluation-of-an-e-mental-health-intervention-for-patients-with-retinal-exudative-diseases-who-receive-intraocular-anti-vegf-injections-e-pseye-protocol-for-a-randomised-controlled-trial
#2
Hilde P A van der Aa, Ger H M B van Rens, Frank D Verbraak, Machteld Bosscha, Marc A Koopmanschap, Hannie C Comijs, Pim Cuijpers, Ruth M A van Nispen
INTRODUCTION: Because of the great potential of vascular endothelial growth factor inhibitors (anti-VEGF) for retinal exudative diseases, an increased number of patients receives this treatment. However, during this treatment, patients are subjected to frequent invasive intravitreal injections, and the effects on reversing the process of vision loss are uncertain, which may have negative consequences for patients' mental health. One in three patients experience at least mild symptoms of depression/anxiety...
November 15, 2017: BMJ Open
https://www.readbyqxmd.com/read/29146306/real-world-vision-in-age-related-macular-degeneration-patients-treated-with-single-anti-vegf-drug-type-for-1-year-in-the-iris-registry
#3
Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W Parke, George A Williams
PURPOSE: The purpose of this study is to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti-vascular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRIS) Registry. DESIGN: Retrospective, nonrandomized, comparative study. PARTICIPANTS: IRIS Registry patients with nAMD who received bevacizumab, ranibizumab, or aflibercept only for 1 year between 2013-2016...
November 13, 2017: Ophthalmology
https://www.readbyqxmd.com/read/29142592/advances-in-age-related-macular-degeneration-understanding-and-therapy
#4
Joan W Miller, Saghar Bagheri, Demetrios G Vavvas
While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive to date, with a lack of effective therapies and increasing prevalence of the disease. There is an overwhelming need to improve the classification system of AMD, to increase our understanding of cell death mechanisms involved in both neovascular and non-neovascular AMD, and to develop better biomarkers and clinical endpoints to eventually be able to identify better therapeutic targets-especially early in the disease process...
2017: US Ophthalmic Review
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#5
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#6
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29134647/serial-profiling-of-circulating-tumor-dna-for-optimization-of-anti-vegf-chemotherapy-in-metastatic-colorectal-cancer-patients
#7
Masami Yamauchi, Yuji Urabe, Atsushi Ono, Daiki Miki, Hidenori Ochi, Kazuaki Chayama
Understanding the molecular changes in tumors in response to anti-VEGF chemotherapy is crucial for optimization of the treatment strategy for metastatic colorectal cancer. We prospectively investigated changes in the amount and constitution of circulating tumor DNA (ctDNA) in serial peripheral blood samples during chemotherapy. Sixty-one plasma samples taken at different time points (baseline, remission, and post-progression) and pre-treatment tumor samples were collected from 21 patients who received bevacizumab-containing first-line chemotherapy...
November 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29131696/risk-factors-for-discontinuation-of-treatment-for-neovascular-age-related-macular-degeneration
#8
Inger Westborg, Aldana Rosso
PURPOSE: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD). METHODS: Data from the Swedish Macula Register and the Skåne Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14 months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree...
November 13, 2017: Ophthalmic Epidemiology
https://www.readbyqxmd.com/read/29130626/age-related-macular-degeneration-using-morphological-predictors-to-modify-current-treatment-protocols
#9
REVIEW
Mohammed Ashraf, Ahmed Souka, Ron A Adelman
To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: 'age related macular degeneration', 'neovascular AMD', 'choroidal neovascular membrane (CNV)', 'anti-vascular endothelial growth factor (anti-VEGF)', 'aflibercept', 'ranibizumab', 'bevacizumab', 'randomized clinical trials', 'post-hoc', 'prognostic', 'predictive', 'response' 'injection frequency, 'treat and extend (TAE), 'pro re nata (PRN)', 'bi-monthly' and 'quarterly'...
November 11, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29129088/systemic-therapy-for-esophagogastric-cancer-targeted-therapies
#10
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) has resulted in an increased focus on the use of targeted agents in this disease. Targets include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), Her2, mammalian target of rapamycin (mTOR), MET, poly (ADP-ribose) polymerase (PARP) and claudin 18.2 (CLDN18.2). Trastuzumab, an anti-Her2 antibody, was approved by the U.S. FDA in 2010 as first-line therapy in combination with chemotherapy for Her2-positive disease...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29127949/effect-of-adding-dexamethasone-to-continued-ranibizumab-treatment-in-patients-with-persistent-diabetic-macular-edema-a-drcr-network-phase-2-randomized-clinical-trial
#11
Raj K Maturi, Adam R Glassman, Danni Liu, Roy W Beck, Abdhish R Bhavsar, Neil M Bressler, Lee M Jampol, Michele Melia, Omar S Punjabi, Hani Salehi-Had, Jennifer K Sun
Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Design, Setting, and Participants: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016...
November 11, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29127485/oct-based-deep-learning-algorithm-for-the-evaluation-of-treatment-indication-with-anti-vascular-endothelial-growth-factor-medications
#12
Philipp Prahs, Viola Radeck, Christian Mayer, Yordan Cvetkov, Nadezhda Cvetkova, Horst Helbig, David Märker
PURPOSE: Intravitreal injections with anti-vascular endothelial growth factor (anti-VEGF) medications have become the standard of care for their respective indications. Optical coherence tomography (OCT) scans of the central retina provide detailed anatomical data and are widely used by clinicians in the decision-making process of anti-VEGF indication. In recent years, significant progress has been made in artificial intelligence and computer vision research. We trained a deep convolutional artificial neural network to predict treatment indication based on central retinal OCT scans without human intervention...
November 10, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29120158/diabetic-macular-edema-traditional-and-novel-treatment
#13
Martina Tomić, Romano Vrabec, Tamara Poljičanin, Spomenka Ljubić, Lea Duvnjak
Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans...
March 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29120156/diabetic-macular-edema-traditional-and-novel-treatment
#14
Martina Tomić, Romano Vrabec, Tamara Poljičanin, Spomenka Ljubić, Lea Duvnjak
Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans...
March 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29117316/vitreous-fibronectin-and-fibrinogen-expression-increased-in-eyes-with-proliferative-diabetic-retinopathy-after-intravitreal-anti-vegf-therapy
#15
Qiaoling Wei, Ting Zhang, Rui Jiang, Qing Chang, Yanqiong Zhang, Xin Huang, Xing Gao, Hong Jin, Gezhi Xu
Purpose: To evaluate vitreous humor (VH) protein expression profiles in patients with proliferative diabetic retinopathy (PDR), with and without intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) before vitrectomy. Methods: We enrolled consecutive PDR patients who needed pars plana vitrectomy (PPV) with or without IVI or pan-retinal photocoagulation (PRP). Visual acuity, duration, and treatment of diabetes mellitus, ocular treatment history, and fundus examinations were recorded...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29115893/the-impact-of-epiretinal-membrane-in-neovascular-age-related-macular-degeneration-treatment-a-spectral-domain-optical-coherence-tomography-study
#16
Irini Chatziralli, Panagiotis Stavrakas, George Theodossiadis, Konstantinos Ananikas, Eleni Dimitriou, Panagiotis Theodossiadis
PURPOSE: The purpose of this prospective study was to evaluate the impact of epiretinal membrane (ERM) on anatomical and functional results in patients with wet age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth (anti-VEGF) injections. METHODS: Participants in the study were 48 patients with either wet AMD alone (AMD group, n = 27) or AMD and ERM (AMD/ERM group, n = 21). All patients received intravitreal anti-VEGF injections (three monthly injections and PRN thereafter) and were followed up for at least 12 months...
November 8, 2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/29111299/diagnosis-and-treatment-guideline-for-myopic-choroidal-neovascularization-due-to-pathologic-myopia
#17
REVIEW
Kyoko Ohno-Matsui, Yasushi Ikuno, Timothy Y Y Lai, Chui Ming Gemmy Cheung
Pathologic myopia is a leading cause of visual impairment. Development of myopic choroidal neovascularization (CNV) is one of the most common complications that leads to central vision loss in patients with pathologic myopia. If left untreated, it can cause scarring with expanding macular atrophy leading to irreversible visual loss in a period as short as 5 years. Advancements in multimodal imaging technology have furthered our understanding of the condition; however, further studies are necessary to extend its utility in the diagnosis of myopic CNV...
October 27, 2017: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/29110201/dexamethasone-intravitreal-implant-in-diabetic-macular-edema-real-life-data-from-a-prospective-study-and-predictive-factors-for-visual-outcome
#18
Irini Chatziralli, Panagiotis Theodossiadis, Efstratios Parikakis, Eleni Dimitriou, Tina Xirou, George Theodossiadis, Stamatina Α Kabanarou
INTRODUCTION: The purpose of the study was to evaluate the long-term anatomical and functional outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implant and to determine the predictive factors for the final visual outcome. METHODS: The study included 54 patients with DME refractory to previous antivascular endothelial growth factor (anti-VEGF) who were treated with intravitreal dexamethasone implant. Predictive factors for visual outcome were assessed...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#19
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29109792/mir-205-yap1-in-activated-fibroblasts-of-breast-tumor-promotes-vegf-independent-angiogenesis-through-stat3-signaling
#20
Yan-E Du, Gang Tu, Guanglun Yang, Genyou Li, Dan Yang, Lei Lang, Lei Xi, Kexin Sun, Yanlin Chen, Kunxian Shu, Huadong Liao, Manran Liu, Yixuan Hou
Tumor microenvironment contributes to tumor angiogenesis. However, the role of the activated cancer associated-fibroblasts (CAFs) in angiogenesis is still unclear. Here we report that miR-205/YAP1 signaling in the activated stromal fibroblasts plays a critical role in VEGF-independent angiogenesis in breast tumor. Methods: miR-205 expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR); YAP1 expression by qRT-PCR, western blotting and immunohistochemistry; IL11 and IL15 expression by qRT-PCR, western blotting and ELISA...
2017: Theranostics
keyword
keyword
35594
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"